Mgliche Nebenwirkungen sind Blhungen, Hautausschlge oder Krmpfe
Teva Pharmaceuticals has launched the first ever generic GLP-1 receptor agonist in the U.S
A 2014 study found that liraglutide treatment for a minimum of 4 weeks in overweight or obese individuals with PCOS resulted in an average weight loss of 9kg and 81.7% lost at least 5% of their starting body weight
In addition to these appetite suppressing effects, Semaglutide has also been shown to improve insulin sensitivity, which is important for those who are overweight or obese and are at risk of developing type 2 diabetes
More serious but less common adverse effects observed in trials or associated with this drug class include: Increased heart rate , a class effect seen with GLP-1 receptor agonists [15] [12] Gallbladder disease , including gallstones (cholelithiasis), which has been associated with rapid weight loss and incretin-based therapies more broadly
It has also been found that Tirzepatide causes more weight loss than Liraglutide